Cantor Fitzgerald began coverage on shares of Xencor (NASDAQ:XNCR) in a report published on Thursday. The brokerage issued a buy rating and a $33.00 target price on the biopharmaceutical company’s stock.
“XNCR announced initiation of a Phase 1 trial of XmAb18087 in subjects with neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST).”,” Cantor Fitzgerald’s analyst commented.
XNCR has been the topic of a number of other research reports. BidaskClub raised Xencor from a strong sell rating to a sell rating in a research note on Wednesday, January 24th. Zacks Investment Research raised Xencor from a sell rating to a hold rating in a research note on Wednesday, November 22nd. Finally, Piper Jaffray Companies reissued a buy rating and issued a $35.00 price target on shares of Xencor in a research note on Sunday, November 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of $30.80.
In other Xencor news, insider Paul A. Foster sold 10,000 shares of Xencor stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $26.03, for a total transaction of $260,300.00. Following the transaction, the insider now owns 12,419 shares of the company’s stock, valued at approximately $323,266.57. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul A. Foster sold 5,000 shares of Xencor stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.01, for a total value of $125,050.00. Following the transaction, the insider now directly owns 7,419 shares in the company, valued at approximately $185,549.19. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 30,804 shares of company stock worth $625,406. Company insiders own 4.14% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Cornerstone Capital Management Holdings LLC. grew its stake in Xencor by 2.3% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock valued at $492,000 after acquiring an additional 521 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Xencor by 6.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,771 shares of the biopharmaceutical company’s stock valued at $629,000 after acquiring an additional 1,673 shares in the last quarter. Nationwide Fund Advisors grew its stake in Xencor by 4.5% during the 3rd quarter. Nationwide Fund Advisors now owns 62,180 shares of the biopharmaceutical company’s stock valued at $1,425,000 after acquiring an additional 2,676 shares in the last quarter. Vident Investment Advisory LLC grew its stake in Xencor by 5.9% during the 4th quarter. Vident Investment Advisory LLC now owns 59,426 shares of the biopharmaceutical company’s stock valued at $1,303,000 after acquiring an additional 3,289 shares in the last quarter. Finally, Swiss National Bank grew its stake in Xencor by 5.2% during the 3rd quarter. Swiss National Bank now owns 66,400 shares of the biopharmaceutical company’s stock valued at $1,522,000 after acquiring an additional 3,300 shares in the last quarter. 77.11% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3223046/xencor-xncr-receives-new-coverage-from-analysts-at-cantor-fitzgerald.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.